Skip to main content
. 2024 Jan 18;30(7):1240–1247. doi: 10.1158/1078-0432.CCR-23-2513

Figure 1.

Figure 1. Treatment exposure and response according to tumor characteristics. A, Olaparib alone. B, Olaparib plus durvalumab. One patient in the olaparib plus durvalumab arm had a germline pathogenic variant in BRCA1 confirmed by the site but reported as a BRCA1 variant of unknown significance and pathogenic PALB2 variant on tumor testing. Each bar represents an individual patient. tBRCA, tumor BRCA.

Treatment exposure and response according to tumor characteristics. A, Olaparib alone. B, Olaparib plus durvalumab. One patient in the olaparib plus durvalumab arm had a germline pathogenic variant in BRCA1 confirmed by the site but reported as a BRCA1 variant of unknown significance and pathogenic PALB2 variant on tumor testing. Each bar represents an individual patient. tBRCA, tumor BRCA.